This week, the Senate HELP Committee held a hearing considering the confirmation of Dr. Heidi Overton to succeed Commissioner Martin Makary in leading the Food and Drug Administration (FDA). Dr. Overton, a physician by trade, most recently served as a senior White House domestic policy advisor. While supporters of Dr. Overton’s leadership point to her deep experience as a potential stabilizer to a volatile policy space, critics worry her close ties to the White House could jeopardize the FDA’s independence. In the hearing, Dr. Overton strongly defended the safety of approved vaccines, avoided committing to future restrictions on reproductive drugs like mifepristone and emphasized her desire to drive further innovation.

The Biggest Question, Scientific Independence

Committee Chairman Senator Bill Cassidy repeatedly questioned Dr. Overton on whether she can truly operate as an independent scientific regulator, or if she will simply be an extension of President Trump. Multiple other senators asked her whether she will resist political pressure from the Administration when it conflicts with science. Dr. Overton responded that while the President sets the policy priorities, the FDA’s job remains to review evidence and take science-based regulatory action.

Vaccines and “Gold Standard Science”

Both Republican and Democratic Senators made clear that they needed to be confident any FDA leader would defend scientific evidence, including against misinformation around vaccine safety. Charman Cassidy asked outright whether Dr. Overton shares the Administration’s inaccurate information around MMR lethality. Dr. Overton emphasized that every vaccine currently on the market, including the MMR vaccine, is safe and effective according to FDA standards.

Medication Access for Women

Several Democratic senators questioned Dr. Overton on her beliefs on mifepristone safety. Dr. Overton said the drug currently meets FDA standards but declined to answer specific questions put forward around telehealth prescribing or potential future restrictions.